LOCAL

ANAESTHETICS
1
2
CASE 1
A 23-year-old female patient is undergoing tooth extraction preceding
her orthodontic treatment (braces for mal-aligned teeth) for cosmetic
purpose.
What should be done prior to her treatment?
DEFINITION :
 Local anesthetics are drugs that cause
reversible loss of sensory perception
specially of pain in a localized area of the
body, when applied topically or through
local injection.

 LA if applied to a mixed nerve—

sensory and motor impulses are
interrupted—resulting in sensory loss as
well as muscular paralysis with loss of
autonomic control.
4
Factors General Anaesthesia Local Anaesthesia
Actions Reversible loss of pain and Reversible loss of pain only
consciousness
Site of action CNS Peripheral nerves
Area of body involved Whole body Localized area
Consciousness Lost Unaltered
Care of vitals Essential Not needed
Poor patient health Risky Safer
In un-cooperative patients Possible Not possible

Major Surgery Preferred Not preferred.

Useful in surgeries below
umbilicus for spinal
anesthesia
Minor Surgery Not preferred Preferred
Examples Neurosurgeries, laparoscopic LSCS, orthopedic surgeries,
surgery, cardio-thoracic dental procedures,
surgeries dermatologic procedures
5
6
CHEMISTRY
Hydrophilic Lipophilic
amine AMIDE
aromatic residue

ESTER

Alkyl Chain

7
8
Esters Amides
Short duration of action and less Produce more intense and longer
intense analgesia lasting analgesia

Higher risk of hypersensitivity, Rarely cause hypersensitivity

rarely used reactions

Hydrolyzed by Plasma esterase in Not hydrolyzed by Plasma

blood Cholinesterase, hydrolysed in liver

Rarely used for Infiltration Bind to alpha1 acid glycoprotein in

anesthesia plasma

But useful for topical anaesthesia on No cross reactivity with ESTER LA

mucous membranes
9
MECHANISM OF ACTION
 It blocks the entry of Na+ during the
upstroke of action potential
 Increasing concentration of LA 
failure to reach the threshold potential
for depolarisation  conduction block
 3 consecutive nodes to be blocked
to prevent impulse propagation
 Blocking action favoured by
depolarisation/nerves that are
repeatedly stimulated than RMP

10
MECHANISM OF ACTION

Voltage gated Na+ channels 11

12
MECHANISM OF ACTION

13
14
FACTORS AFFECTING THE ACTION OF
LOCAL ANESTHETICS

1. LIPID SOLUBILITY
 All local anaesthetics are weak bases. Increasing the lipid
solubility leads to faster nerve penetration, and speed up the
onset of action.
So, the more unionized form present, the faster the onset
action.

15
2. pH INFLUENCE
 Usually at range 7.6 – 8.9
 Decrease in pH shifts equilibrium toward the ionized
form, delaying the onset action.
 Presence of pus and inflammation will retard the action of
LA. (lower acidic pH)
 Sometimes, LA is administered with bicarbonate to
increase the unionized fraction and thus efficacy.

16
3. EFFECT OF VASOCONSTRICTION
 Vasoconstrictor used  epinephrine (adrenaline)
 Due to vasoconstriction at the site of required local anesthesia,
there is delayed removal of LA from the local site into the
circulation.
 It reduces the systemic toxicity of Local Anesthetic.
 It provides a relatively bloodless field for surgery.
 It keeps the aneasthetic solution at the site of action for a
longer period - It increases the contact time of LA with the nerve
fibre.
 Other – felypressin (no change in HR, BP, CO), clonidine
17
When not to combine LA +
Vasoconstrictor?
 Increased chances of local tissue
edema, necrosis
 Not to be added in surgeries where end
arteries are involved (fingers, tip of the
nose, earlobe, penis)
 Delays wound healing by reducing the
oxygen supply
 In susceptible individuals - raises BP
and promotes arrhythmia

18
 NERVE FIBER AND LOCAL ANESTHETIC EFFECTS
 Fiber diameter - larger
the fiber the higher the
concentration of LA
required
 Non-myelinated fibers
are blocked earlier than
myelinated nerve fibers
 Autonomic fibers are
more susceptible than
somatic
 Recovery in reverse order
19
SEQUENCE OF BLOCKADE
Reversible loss of 

20
 SYSTEMIC ACTIONS
1. CNS
 Stimulation followed by depression (initial blockade of
inhibitory fibres)
 Cocaine - powerful CNS stimulant
 Euphoria  excitement  mental confusions  restlessness 
tremor  twitching of muscles  convulsions  unconsciousness
 respiratory depression  death in a dose-dependent manner

21
 Lignocaine – circumoral numbness, drowsiness, lethargy,
tinnitus, blurred vision

 Higher doses – excitation, restlessness, agitation, muscle

twitching, seizures, unconsciousness

22
2. CVS
 Cardiac depressants
 High doses – decrease
automaticity, excitability,
contractility, conductivity
 Procainamide, lignocaine –
antiarrhythmic – Class Ib
 Bupivacaine - cardiotoxic,
ventricular arrhythmia

23
3. BLOOD VESSELS
 Sympathetic blockade - Fall in BP
 Toxic doses - cardiovascular collapse
 Cocaine - sympathomimetic, rise in BP, tachycardia

24
PHARMACOKINETICS
 Soluble surface anesthetics are rapidly absorbed via mucous
membrane and abraded skin
 Ester LA are rapidly hydrolysed by plasma esterase
 Amide LA are bound to alpha1 acid glycoprotein in plasma
 They undergo dealkylation and hydrolysis in the liver
 Procaine & lignocaine- 1st pass metabolism is high
 Esters have greater duration of action in CSF as CSF doesn’t
contain esterases.

25
ADVERSE EFFECTS
 CNS - light-headedness, dizziness, auditory and visual
disturbances, mental confusion, disorientation, shivering,
twitchings, involuntary movements, finally convulsions and
respiratory arrest
 CVS - bradycardia, hypotension, cardiac arrhythmias,
vascular collapse
 Local tissue damage
 Hypersensitivity reaction
 Accidental injection into artery/vein  treatment?
26
DRUG INTERACTION
 Beta blockers reduce hepatic blood flow, hence reduce
the metabolism of local anesthetics.

 Rise in BP occurs when vasoconstrictor containing LA

is given to patients with ischemic heart disease, cardiac
arrhythmia, thyrotoxicosis, uncontrolled hypertension,
those on beta blockers, on tricyclic antidepressants

27
LIGNOCAINE ( XYLOCAINE )
 Most widely used amide linked LA
 When used locally action starts within 3 minutes
 Vasodilatation occurs at the injected site
 Intermediate duration of action
 Maximal recommended dose: 3 mg/kg, 6 mg/kg with
vasconstrictor

28
 Applications: surface
application, infiltration,
nerve block, spinal, epidural,
IVRA
 Class Ib antiarrhythmic
properties
 Overdose causes muscle
twitchings, convulsions,
cardiac arrhythmias, fall in
BP, coma, respiratory arrest.

29
 Lidocaine transdermal patch (LIDODERM)- relief of pain
associated with postherpetic neuralgia

 Oral patch (DENTIPATCH) - application to accessible mucous

membranes of mouth prior to superficial dental procedures

 In combination with tetracaine (PLIAGLIS) as a "peel" is

approved for topical local analgesia prior to superficial
dermatological procedures such as filler injections and laser-
based treatments.
31
32
 In combination with tetracaine
- in a formulation that generates
heat upon exposure to air
(SYNERA 70/70mg)  better
drug penetration

 Used prior to venous access

and superficial dermatological
procedures such as excision,
electrodessication, and shave
biopsy of skin lesions.

33
E M L A Cream :
 Eutectic Mixture of Local Anesthetic,
combination of Lidocaine and Prilocaine – equal
quantity by weight
 The mixture has lower melting point than either
of the ingredients alone. Can penetrate intact skin
 For Pediatric purpose.
 IV cannula inserting.
 Split skin graft harvesting.
 Other superficial procedures.

34
 BUPIVACAINE
 A potent long acting - Amide linked
LA available in India, most widely used
 Not used for IVRA but all others like
local, spinal epidural blocks.
 Action lasts for 2 to 3 hours. Strength for
epidural is 0.25 to 0.5 % solution.
 Has high lipid solubility, distributes
more in tissues than in blood

35
 Causes more sensory block, than motor block the advantage
taken in during Caesarean Section, painless labour
 More prone to prolong QTc interval and induce ventricular
tachycardia or Cardiac depression
 Long duration of action, no need for repetitive doses
 Hard to resuscitate, large doses of inotropes required
 Plain / hyperbaric (5% Glucose)
 Max recomm. Dose: 2 mg/kg

36
THERAPEUTIC USES :

37
CASE 2
A 67 year old patient is rushed to emergency with c/o sudden onset mental
confusion, trouble speaking, muscle weakness and inability to walk or move
his right arm. He was seen by medicine faculty and initial clinical
examination was suggestive of stroke. You are an intern working in
emergency ward and was asked to put IV line and catheterize the bladder of
the patient. You directly start introducing the catheter but the matron stops
you from doing so and corrects you. Which important step have you
missed?
1. SURFACE ANESTHESIA
 Only the superficial layer is anesthetized; no
loss of function of motor function
 Amethocaine - eye, throat, urethra, rectum and
skin.
 Benzocaine and Lidocaine hydrochloride -
except for eye.
 Procaine is unsuitable as a surface anesthesia.
Because of its poor penetrating power
 Lignocaine (E M L A Cream )

39
2. INFILTRATION ANAESTHESIA :
 Dilute solution of LA is infiltrated under the skin
in the area of operation so that sensory nerve
endings are blocked
 Done in minor surgeries: Incisions, excisions,
hydrocele, herniorraphy
 Bupivacaine, Lignocaine 2 % are used either with
or without Adrenaline 1 : 2,00,000
 C/I : blocking where end arteries are involved
either for Penis, or for Digits, CAD patients

40
CASE 3
34-year-old female patient presented to surgical OPD with
ingrowing toenail. She underwent surgical removal of the
toenail after ring block using 2% Lignocaine.
Why is a combination of lignocaine with adrenaline not
used for ring block? Name other sites where this
combination is contraindicated for infiltration.
3. CONDUCTION BLOCK
 Field block & Nerve block
Drug is injected close to the nerve or big nerve trunks eg.
Brachial Block, Sciatic, Femoral Nerve, Radial, Ulnar Nerves
 Eg Lignocaine, bupivacaine

42
Axillary nerve glassopharyngeal nerve

Superior Laryngeal Nerve Median Nerve

43
CASE 4
A 25 yr old fit male patient if posted for elective
appendicectomy. What is the route of choice of anesthesia

44
4. SPINAL ANESTHESIA
 LA is injected into the
subarachnoid space at the level of L4
– L5. Injection is made heavy by
adding dextrose or light by adding
saline.
 When the anesthetic in injected
outside the dura, the technique is
known as Epidural anesthesia.
 Lignocaine, bupivacaine the two
agents most commonly used
regularly in anesthesia practice.
45
46
COMPLICATIONS OF SPINAL ANESTHESIA
1. Headache – CSF leak
2. Hypotension – sympathetic vasoconstriction, venous pooling
3. Cauda Equina Syndrome – loss of control over bladder and
bowel sphincter due to traumatic damage to nerve roots or
antiseptic in Subarachnoid space
4. Respiratory paralysis – hypotension and ischemia of
respiratory centers
5. Septic meningitis
6. Nausea and vomiting - reflexes triggered by traction on
abdominal viscera 47
Contraindications:
[Link], hypovolemia
[Link] or mentally ill patients
[Link] diathesis
[Link] IOP
[Link] anomalies

48
CASE 5
A 24 yr old primigravida is in 8th month of pregnancy is
seeking for a safe vaginal delivery for long term benefits
over caesarean section. But she is scared of the intensity of
labor pain.
What form of anesthesia can be advised to her?

49
5. EPIDURAL ANESTHESIA
 Here the drug is injected
outside the dura. Drug
spread is restricted to a
specific region causes fewer
complications
 Bupivacaine
 Types: Cervical,
Thoracic, Lumbar, Caudal

50
51
52
 6. I V R A (BIER’S BLOCK)
 Intravenous regional anesthesia
 Agent of choice - Lignocaine
(Xylocaine )
 20 to 40 ml of 0.5 % Lidocaine
is used
 Used for only for Upper Limb
orthopedic surgeries and others on
Up. Limb.
53
54
55
56
THANK
YOU
57
Miosis, or constriction of the pupils, can be caused by both morphine and pilocarpine, but the
mechanisms behind their actions differ. Here are the key points to differentiate miosis caused by
morphine from that caused by pilocarpine:
1. Mechanism of Action:
: Morphine is an opioid that works by binding to opioid receptors (mainly μ-receptors) in the
•Morphine

brain and spinal cord. This binding activates a cascade that leads to pupil constriction. It affects the
central nervous system (CNS) and the parasympathetic pathway that controls the pupil via the
Edinger-Westphal nucleus.
•Pilocarpine: Pilocarpine is a muscarinic cholinergic agonist that directly stimulates the muscarinic
receptors (M3 receptors) on the iris sphincter muscle, leading to pupil constriction. It acts
peripherally, directly on the parasympathetic system.
2. Pupil Size and Response:
: The miosis caused by morphine typically results in pinpoint pupils, which are very small,
•Morphine

often described as "opioid pupils." This is due to the central action of opioids on the CNS.
•Pilocarpine: Pilocarpine causes a more uniform constriction of the pupil. The pupils may constrict
normally in size but may also become tightly constricted (miosis), depending on the dosage. The
constriction is more pronounced and noticeable under bright light.
3. Reversibility and Effects of Antagonists:
: The miosis caused by morphine can be reversed with the administration of naloxone, an
•Morphine

opioid antagonist. This will restore normal pupil size.

•Pilocarpine: The miosis caused by pilocarpine can be reversed by the use of atropine or other
anticholinergic drugs that block the muscarinic receptors.
58
4
. Associated Signs and Symptoms:
: In addition to miosis, morphine typically causes other signs of opioid intoxication, such as
•Morphine

sedation, respiratory depression, altered mental status, euphoria, and analgesia.

•Pilocarpine: Pilocarpine use is associated with signs of cholinergic effects, such as increased
salivation, sweating, bradycardia, and gastrointestinal distress (e.g., nausea, vomiting),
especially in higher doses.
5. Onset of Action:
: Miosis from morphine generally appears within minutes after administration, especially in
•Morphine

those who are opioid-naive.

•Pilocarpine: Miosis caused by pilocarpine typically occurs within minutes after topical application
and is more local in its effects.
6. Use in Clinical Practice:
: Miosis due to morphine is seen in cases of opioid overdose or in patients receiving morphine
•Morphine

for pain management.

•Pilocarpine: Pilocarpine is used clinically as a glaucoma medication and sometimes in diagnostic
tests for cranial nerve dysfunction or to treat dry mouth in certain conditions like Sjögren's
syndrome.
Summary:
is caused by the central effects of opioids on the CNS and results in pinpoint pupils
•Morphine-induced miosis

•Pilocarpine-induced miosis is caused by the direct stimulation of the muscarinic receptors on the
iris sphincter muscle, leading to more generalized and tight pupil constriction. 59
•The clinical context, associated symptoms, and response to specific antagonists (naloxone for
1. Mechanism of Miosis from Morphine:
central nervous system (CNS), specifically in the
•When morphine is taken systemically, it binds to opioid receptors in the

brainstem. This interaction stimulates the Edinger-Westphal nucleus, which leads to

parasympathetic stimulation and the constriction of the pupil, resulting in miosis (pinpoint
pupils).
•However, morphine's effect is primarily central. For it to induce significant miosis, it needs
to reach the brain and spinal cord in sufficient amounts.
2. Topical Administration of Morphine (Eye Drops):
eye drops, it is applied locally to the eye and typically affects the ocular
•When morphine is given as

tissues, such as the cornea and conjunctiva. Only a small amount of morphine is absorbed into
the systemic circulation from the eye, and the concentration in the CNS is much lower.
•The local action of morphine on the eye is generally limited to analgesic effects (pain relief)
in the treatment of eye conditions, rather than affecting pupil size.
3. Pupil Effects from Eye Drops:
miosis as seen with systemic morphine. Any minor
•Morphine in eye drops is not likely to produce the same pronounced

pupil constriction, if it occurs, would be due to the local effects on the eye, not the systemic
opioid action.
•Pilocarpine, which is commonly used in eye drops for treating glaucoma, works by stimulating
the parasympathetic nervous system and directly causing pupil constriction. In contrast,
morphine’s action is more related to the CNS and is not effective at causing miosis when applied
topically.
Conclusion:
systemic
Morphine given as eye drops is unlikely to cause miosis due to its limited systemic absorption and central action. Miosis typically occurs with
60
morphine, not with local application to the eye. If miosis occurs in such a case, it would likely be
Feature Lidocaine Cocaine
Sodium channel blocker Sodium channel blocker +
Anesthetic Action
(local anesthetic) sympathomimetic
Causes mydriasis (pupil
Pupil Effect No effect on pupil size
dilation)
Significant
None (unless combined
Vasoconstriction vasoconstriction
with epinephrine)
(blanching of conjunctiva)
CNS stimulation,
Systemic Effects Rare, typically none tachycardia, increased
blood pressure
Local anesthesia +
Local anesthesia for
Clinical Use diagnostic purposes (e.g.,
ocular procedures
Horner’s syndrome) 61
The procaine component of procaine penicillin serves primarily as a local anesthetic and also affects the rate of absorption of penicillin.
Here are the key roles of procaine in procaine penicillin:
1. Local Anesthetic Effect:
•Procaine is a local anesthetic that works by blocking sodium channels in nerve cells, preventing the initiation and conduction of nerve impulses. This provides temporary numbness
in the area where the injection is administered.
•When combined with penicillin, procaine helps reduce the pain or discomfort associated with the intramuscular injection of the antibiotic, which can be quite painful on its own.

2. Slowing Penicillin Absorption:

•Procaine helps to slow the absorption of penicillin from the injection site. This allows for prolonged release of penicillin into the bloodstream.
•The slower absorption helps maintain sustained blood levels of penicillin over time, which can be beneficial for treating infections that require longer periods of antibiotic action. This
results in a long-acting effect of penicillin, typically lasting 12 to 24 hours, depending on the formulation.

3. Enhancing Penicillin's Duration of Action:

•By delaying the absorption, procaine penicillin allows for less frequent dosing compared to regular penicillin formulations. This is particularly useful for treating infections where
prolonged antibiotic levels are required but the patient needs fewer injections.

4. Combination Benefits:
•The combination of penicillin (an antibiotic) and procaine (a local anesthetic) in procaine penicillin provides both the therapeutic effects of the antibiotic and the relief of injection-
related pain. This combination is particularly useful in intramuscular injections of penicillin, which can otherwise be quite painful and difficult to tolerate for patients.

Clinical Use:
•Procaine penicillin is often used to treat a variety of infections, including syphilis, streptococcal infections, and rheumatic fever.
•The slower release and the reduced pain associated with the injection make it a preferred option for certain patients who need long-acting penicillin therapy but may have difficulty with
the pain of frequent injections.

Summary:
The procaine part of procaine penicillin serves as a local anesthetic to reduce pain at the injection site and helps slow the absorption of penicillin, leading to a longer duration of
action and reduced frequency of dosing.

62
Dose Range Effects

D1 receptor stimulation: Renal and

mesenteric vasodilation, increased renal
Low Dose (1–5 µg/kg/min)
perfusion and urine output, no significant blood
pressure effect.

D1 & β1 receptor stimulation: Increased

heart rate and contractility, mild increase in
Moderate Dose (5–10 µg/kg/min) cardiac output, mild vasoconstriction leading
to a modest rise in blood pressure, enhanced
renal perfusion.

β1 & α1 receptor stimulation: Strong

positive inotropic and chronotropic effects,
High Dose (10–20 µg/kg/min or higher) marked vasoconstriction leading to a
significant increase in blood pressure, potential
reduction in renal perfusion at very high doses.

63
Lidocaine (also known as lignocaine) is not typically used to treat atrial arrhythmias because of its mechanism of action and the specific characteristics of atrial
tissues. Here are the key reasons why lidocaine is not effective for atrial arrhythmias:
1. Selective Effect on Ventricular Tissue:
•Lidocaine is a Class 1b antiarrhythmic drug, and its primary action is to block sodium channels. It preferentially affects damaged or depolarized tissues
(such as those in the ventricles during arrhythmias), and it has a stronger effect on ventricular tissue compared to atrial tissue.
•Lidocaine works best in areas where sodium channels are in the activated or inactivated state, such as in ischemic or depolarized tissues, which are more
commonly found in ventricular arrhythmias. Since atrial tissue is often not as depolarized in atrial arrhythmias, lidocaine is less effective at treating them.

2. Shortened Action Potential Duration:

•Lidocaine shortens the action potential duration in cardiac tissues. While this is helpful in ventricular arrhythmias (where a prolonged action potential can
contribute to reentrant circuits), it can be counterproductive for atrial arrhythmias.
•Atrial arrhythmias, like atrial fibrillation (AF) or atrial flutter, often involve rapid atrial firing and reentry circuits. In these arrhythmias, a longer action
potential duration and refractory period in the atria are typically required to terminate the arrhythmia or prevent reentry.
•By shortening the refractory period, lidocaine could potentially facilitate the reentry circuits that sustain atrial arrhythmias, worsening the condition.

3. Effect on Atrial vs. Ventricular Tissue:

•Atrial tissue has fewer sodium channels than ventricular tissue, and it is less prone to depolarization in many atrial arrhythmias. Lidocaine's effect is more
significant in tissues with high sodium channel density, which is more characteristic of ventricular myocardium.
•In atrial arrhythmias, where rapid atrial activity (such as in atrial fibrillation) is the primary concern, slowing conduction and prolonging the refractory
period in the atria are more important for controlling the arrhythmia. Lidocaine, which primarily works to shorten conduction in atrial tissue, would not be effective
in controlling or terminating atrial fibrillation.

4. Alternative Medications for Atrial Arrhythmias:

•For atrial arrhythmias, other antiarrhythmic drugs are more effective than lidocaine. These include:
•Class 1a antiarrhythmics (e.g., quinidine, procainamide) that slow conduction and prolong the action potential in atrial tissues, which can help control
atrial arrhythmias.
•Class 3 antiarrhythmics (e.g., amiodarone, sotalol) that prolong the refractory period and help prevent reentrant circuits in atrial fibrillation and
flutter.
•Calcium channel blockers (e.g., diltiazem, verapamil) and beta-blockers (e.g., metoprolol) are also used to rate control in atrial arrhythmias like
atrial fibrillation, as they slow down the ventricular response without affecting atrial conduction as much.

5. Limited Efficacy for Atrial Fibrillation and Flutter:

•Lidocaine is not generally used for atrial fibrillation (AF) or atrial flutter because it does not address the underlying electrical abnormalities in the atria
effectively.
•In atrial fibrillation, multiple ectopic foci and reentrant circuits lead to irregular electrical activity, and lidocaine's sodium channel blockade is more
beneficial in ventricular arrhythmias, where it can suppress ectopic foci and stabilize ventricular conduction.

Conclusion:
Lidocaine is not used for atrial arrhythmias because it shortens the action potential and refractory period, which can worsen atrial arrhythmias. It primarily
works on ventricular tissue, and its effects are more beneficial for ventricular arrhythmias (such as ventricular tachycardia or ventricular fibrillation), where
the goal is to slow conduction and prevent reentry in damaged ventricular myocardium. For atrial arrhythmias, other medications that prolong the refractory
period and restore normal atrial rhythm are preferred.
64
Here is a detailed breakdown of the dose-related effects of dopamine:
1. Low Dose (1–5 µg/kg/min):
At low doses, dopamine predominantly stimulates dopamine receptors (D1 and D2).
•Vasodilation: Dopamine primarily stimulates D1 receptors in the renal, mesenteric, coronary, and cerebral vasculature, leading to vasodilation. This increases blood flow to the
kidneys, intestines, heart, and brain, and is particularly important in patients with shock or acute heart failure, where maintaining perfusion to vital organs is crucial.
•In the kidneys: This vasodilation can lead to increased renal blood flow and increased glomerular filtration rate (GFR), promoting diuresis (increased urine output).
•Increase in Heart Rate (Mild): While the effect on heart rate is less pronounced at low doses, some indirect effects can cause a mild increase in heart rate due to the sympathetic
stimulation caused by D1 receptor activation.
•Increased Renal Perfusion: Dopamine's action on the kidneys also leads to increased urinary sodium excretion and promotes fluid balance, making it useful in conditions like acute
renal failure.
•No Significant Effect on Blood Pressure: In general, blood pressure may remain unchanged at low doses, since vasodilation predominates. However, the overall effect on blood
pressure is minimal at this dose.

2. Moderate Dose (5–10 µg/kg/min):

At moderate doses, dopamine stimulates both D1 receptors (to a lesser extent than at low doses) and β1-adrenergic receptors.
•Positive Inotropic Effect: Activation of β1-adrenergic receptors in the heart results in increased heart rate (positive chronotropic effect) and increased contractility (positive
inotropic effect), leading to a mild increase in cardiac output. This can be helpful in conditions where there is low cardiac output, such as in shock or heart failure.
•Mild Vasodilation and Vasoconstriction: At moderate doses, dopamine can also cause mild vasodilation in the kidneys, mesenteric vessels, and heart, but at the same time, β1
stimulation leads to some mild vasoconstriction in the systemic vasculature. This can slightly increase the mean arterial pressure (MAP), though the vasoconstriction is less
pronounced than at higher doses.
•Mild Increase in Blood Pressure: The combined effects of increased heart rate and mild vasoconstriction lead to a modest increase in blood pressure. This is particularly
beneficial in treating hypotension due to shock or in patients with heart failure.
•Improved Perfusion: The moderate dose also continues to enhance renal perfusion and urinary output, although these effects are less pronounced compared to the low-dose
range.

3. High Dose (10–20 µg/kg/min or higher):

At higher doses, dopamine activates both β1-adrenergic receptors and α-adrenergic receptors more strongly, leading to more pronounced effects.
•Strong Positive Inotropic and Chronotropic Effects: At higher doses, β1 receptor stimulation increases the heart's contractility and rate more significantly, leading to a
substantial increase in cardiac output. This can be beneficial in cardiogenic shock or in patients with severe heart failure who require significant circulatory support.
•Vasoconstriction: Activation of α1-adrenergic receptors at high doses causes vasoconstriction in the systemic vasculature, leading to an increase in blood pressure (both systolic
and diastolic). This can be helpful in cases of severe hypotension or shock (e.g., septic shock) where blood pressure support is needed.
•Marked Increase in Blood Pressure: The combination of β1-induced increased cardiac output and α1-induced vasoconstriction results in a significant increase in systemic
vascular resistance and mean arterial pressure (MAP). This is particularly useful in treating shock or acute hypotension in critical care settings.
•Decreased Renal Perfusion at Very High Doses: At very high doses, the vasoconstrictive effects from α1 stimulation can actually reduce renal blood flow, potentially
compromising kidney function in patients who are already at risk for acute renal failure. This highlights the importance of carefully managing the dose.

Summary of Dose-Dependent Effects of Dopamine:

Clinical Uses of Dopamine (Based on Dose):

•Low Dose: Used in acute renal failure to enhance renal perfusion, often in critical care or shock settings.
•Moderate Dose: Used in heart failure or shock to increase cardiac output and support blood pressure, while maintaining renal perfusion.
•High Dose: Used in severe hypotension or shock (e.g., septic shock or cardiogenic shock) to increase blood pressure and support circulation.

Conclusion: 65
The effects of dopamine are dose-dependent and vary based on its action on different receptor types. At low doses, it primarily affects renal and mesenteric vasodilation, while at